GetTopicDetailResponse(id=e2f124e449, topicName=anakinra, introduction=anakinra, content=null, image=null, comments=4, allHits=1612, url=https://h5.medsci.cn/topic?id=2474, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=77944, tagList=[TagDto(tagId=77944, tagName=anakinra)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2268699, encodeId=53fb226869966, content=<a href='/topic/show?id=ea86482116d' target=_blank style='color:#2F92EE;'>#巨細胞動脈炎#</a> <a href='/topic/show?id=e2f124e449' target=_blank style='color:#2F92EE;'>#anakinra#</a>, objectTitle=Arthritis Res Ther：Anakinra聯(lián)合糖皮質(zhì)激素治療4個月未改善巨細胞動脈炎復(fù)發(fā)率和激素停用率, objectType=article, longId=881642, objectId=f9ba8816424e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250219/1739954389280_8538692.jpg, objectUrl=/article/show_article.do?id=f9ba8816424e, replyNumber=0, likeNumber=32, createdTime=2025-06-10, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f9ba8816424e, moduleTitle=Arthritis Res Ther：Anakinra聯(lián)合糖皮質(zhì)激素治療4個月未改善巨細胞動脈炎復(fù)發(fā)率和激素停用率, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f9ba8816424e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2118802, encodeId=013e211880250, content=<a href='/topic/show?id=e2f124e449' target=_blank style='color:#2F92EE;'>#anakinra#</a>用于<a href='/topic/show?id=f52851329b' target=_blank style='color:#2F92EE;'>#Covid-19#</a>相關(guān)繼發(fā)性<a href='/topic/show?id=20cf105599ee' target=_blank style='color:#2F92EE;'>#噬血細胞淋巴組織細胞增多癥#</a>, objectTitle=2020 NICE 證據(jù)總結(jié)：Anakinra用于COVID-19相關(guān)繼發(fā)性噬血細胞淋巴組織細胞增多癥【ES26】, objectType=guider, longId=22848, objectId=cae611c003020959, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=cae611c003020959, replyNumber=0, likeNumber=161, createdTime=2023-03-11, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=cae611c003020959, moduleTitle=2020 NICE 證據(jù)總結(jié)：Anakinra用于COVID-19相關(guān)繼發(fā)性噬血細胞淋巴組織細胞增多癥【ES26】, moduleType=guider, hrefUrl=http://ermita.cn/guideline/show_article.do?id=cae611c003020959)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517116, encodeId=279e151e1168b, content=<a href='/topic/show?id=e2f124e449' target=_blank style='color:#2F92EE;'>#anakinra#</a>, objectTitle=CHMP對 Kineret (anakinra) 治療COVID-19持積極意見, objectType=article, longId=292250, objectId=43db292250ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43db292250ee, replyNumber=0, likeNumber=93, createdTime=2021-12-21, rootId=0, userName=12498e67m31暫無昵稱, userId=7b0211025450, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43db292250ee, moduleTitle=CHMP對 Kineret (anakinra) 治療COVID-19持積極意見, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=43db292250ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517115, encodeId=0536151e11582, content=<a href='/topic/show?id=e2f124e449' target=_blank style='color:#2F92EE;'>#anakinra#</a>, objectTitle=Lancet Rheumato：Anakinra治療重癥新冠肺炎患者, objectType=article, longId=195185, objectId=262d19518599, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262d19518599, replyNumber=0, likeNumber=102, createdTime=2020-06-04, rootId=0, userName=12498e67m31暫無昵稱, userId=7b0211025450, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262d19518599, moduleTitle=Lancet Rheumato：Anakinra治療重癥新冠肺炎患者, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=262d19518599)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517114, encodeId=0fa1151e11437, content=<a href='/topic/show?id=e2f124e449' target=_blank style='color:#2F92EE;'>#anakinra#</a>, objectTitle=Kineret（anakinra）在英國批準用于罕見炎癥性疾病的治療, objectType=article, longId=144574, objectId=7bab1445e406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bab1445e406, replyNumber=0, likeNumber=103, createdTime=2018-07-18, rootId=0, userName=12498e67m31暫無昵稱, userId=7b0211025450, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bab1445e406, moduleTitle=Kineret（anakinra）在英國批準用于罕見炎癥性疾病的治療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=7bab1445e406)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
